Safety and Efficacy Study of RT001 to Treat Moderate to Severe Lateral Canthal Lines

Exclusion Criteria

• •Muscle weakness or paralysis in the area receiving study treatment
• •Active skin disease or irritation at the treatment areas
• •Undergone any procedures that may affect the lateral canthal region during the past 12 months prior to Screening
• •Previous treatment with botulinum toxin (any serotype) in the head or neck area within 9 months prior to Baseline (Day 0)
• •Use of a topical steroid on either of the treatment areas or use of medications that suppress the immune system 30 days prior to Screening and continuing through End of Study (Day 28)
• •Any abnormality on the electrocardiogram (ECG) at Screening or any history of clinically significant arrhythmia, unstable angina, myocardial infarction or congestive heart failure